2型糖尿病患者的联合降血压疗法:来自ADVANCE试验的信息
Nelson Wang1,2,3, John Chalmers1, Katie Harris1
1The George Institute for Global Health, UNSW.
Journal of hypertension
|September 9, 2024
概括
在ADVANCE试验中发现,强化降低血压,使用百普林-英达巴胺,在2型糖尿病患者中显著降低了心血管,和死亡事件. 这种组合疗法对于在这个人群中管理高血压至关重要.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 2型糖尿病 (T2D) 与心血管和脏风险的增加有关.
- 有效的血压管理对于减少T2D的并发症至关重要.
- 之前的研究强调了在T2D中需要最佳的抗高血压策略.
研究的目的:
- 评估在患有T2D的患者中,使用固定剂量的印布里尔-英达巴米德组合与安慰剂的密集血压降低的疗效.
- 确定新的风险标志物和T2D中高血压管理的实际方面.
主要方法:
- 糖尿病和血管疾病中的作用: preterAx和diamicroN控制评估 (ADVANCE) 试验涉及大量T2D患者.
- 一个随机的,安慰剂控制的设计被用来评估结合印布里尔-达巴胺治疗的效果.
- 二次分析探讨了风险标志物和治疗影响.
主要成果:
- 结合印布里尔-英达帕米德疗法显著减少了主要的心血管,和死亡事件.
- 在各种患者子组中观察到一致的相对风险降低.
- 确定了新的风险标志物和对BP管理的见解.
结论:
- 密集的血压降低与二-英达巴胺为T2D患者提供了巨大的好处.
- ADVANCE的发现为优化高血压管理和T2D的联合治疗提供了基础.
- 了解风险标志物和实际治疗方面可以改善患者的治疗结果.
相关概念视频
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
Antihypertensive Drugs: Action of Diuretics
630
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
630
Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398


